Skip to main content
logo
Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
15.55
+0.02 (0.13%)
Nov 7, 2025, 4:00 PM EST - Market closed

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
U.S. and Puerto Rico Revenue
-2.41B
Log In
Log In
Log In
Upgrade
Total International Revenue
-2.38B
Log In
Log In
Log In
Upgrade
Revenue (Total)
-4.79B
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Vision Care Revenue
2.87B2.74B
Log In
Log In
Log In
Upgrade
Surgical Revenue
876.00M843.00M
Log In
Log In
Log In
Upgrade
Ophthalmic Pharmaceuticals Revenue
1.23B1.21B
Log In
Log In
Log In
Upgrade
Revenue (Total)
-4.79B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Pharmaceuticals Revenue
1.03B969.00M
Log In
Log In
Log In
Upgrade
Devices Revenue
1.88B1.80B
Log In
Log In
Log In
Upgrade
OTC Revenue
1.81B1.72B
Log In
Log In
Log In
Upgrade
Branded and Other Generics Revenue
240.00M281.00M
Log In
Log In
Log In
Upgrade
Total Product Revenue
4.96B4.77B
Log In
Log In
Log In
Upgrade
Other Product Revenue
19.00M17.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
-4.79B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Vision Care Segment Profit
839.00M808.00M
Log In
Log In
Log In
Upgrade
Surgical Segment Profit
19.00M44.00M
Log In
Log In
Log In
Upgrade
Ophthalmic Pharmaceuticals Segment Profit
180.00M256.00M
Log In
Log In
Log In
Upgrade
Corporate Segment Profit
-652.00M-614.00M
Log In
Log In
Log In
Upgrade
Amortization of Intangible Assets
-270.00M-288.00M
Log In
Log In
Log In
Upgrade
Net Other Expense
-28.00M-44.00M
Log In
Log In
Log In
Upgrade
Operating Income (Total)
-162.00M
Log In
Log In
Log In
Upgrade

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Vision Care Capital Expenditures
--
Log In
Log In
Log In
Upgrade
Surgical Segment Expenditures
--
Log In
Log In
Log In
Upgrade
Ophthalmic Pharmaceuticals Capital Expenditures
--
Log In
Log In
Log In
Upgrade
Corporate Capital Expenditures
--
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212017 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2020
Vision Care Revenue Change in Constant Currency
-10.00%
Log In
Log In
Log In
Upgrade
Surgical Revenue Change in Constant Currency
-11.00%
Log In
Log In
Log In
Upgrade
Ophthalmic Pharmaceuticals Revenue Change in Constant Currency
-45.00%
Log In
Log In
Log In
Upgrade
Total Revenue Change in Constant Currency
-17.00%
Log In
Log In
Log In
Upgrade
Vision Care Revenue Organic Change
--
Log In
Log In
Log In
Upgrade
Ophthalmic Pharmaceuticals Revenue Organic Change
--
Log In
Log In
Log In
Upgrade
Surgical Revenue Organic Change
--
Log In
Log In
Log In
Upgrade
Total Revenue Organic Change
--
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.